QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 25, no. 2 (2006): 325-336
doi: 10.1377/hlthaff.25.2.325
© 2006 by Project HOPE
 
New Online
 * May/June Issue: Health Reform Revisited
 * Reform and '08 Election
 * Promoting off-label drug use information
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Online Appendices
* Media/Policy Briefing
* Submit a response to this article
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (2)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Laxminarayan, R.
* Articles by Smith, D. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Laxminarayan, R.
* Articles by Smith, D. L.
Related Collections
* Business Of Health
* Consumer Issues
* Health Promotion/Disease Prevention
* Health Reform
* International Issues
* Legal/Regulatory Issues
* Vaccines
* Pharmaceuticals
* Public Health
* Research And Technology
* Health Spending

Drugs/Vaccines

Will A Global Subsidy Of New Antimalarials Delay The Emergence Of Resistance And Save Lives?

Ramanan Laxminarayan, Mead Over and David L. Smith

Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
A. Bosman and K. N. Mendis
A Major Transition in Malaria Treatment: The Adoption and Deployment of Artemisinin-Based Combination Therapies
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 193 - 197.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
H. Gelband and A. Seiter
A Global Subsidy for Antimalarial Drugs
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 219 - 221.
[Abstract] [Full Text] [PDF]



Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2006 Project HOPE–The People-to-People Organization
Terms and Policies